The SARS–CoV–2 virus is released from an infectious source(such as a sick person)and adsorbed on aerosols,which can form pathogenic microorganism aerosols,which can affect human health through airborne transmission....The SARS–CoV–2 virus is released from an infectious source(such as a sick person)and adsorbed on aerosols,which can form pathogenic microorganism aerosols,which can affect human health through airborne transmission.Efficient sampling and accurate detection of microorganisms in aerosols are the premise and basis for studying their properties and evaluating their hazard.In this study,we built a set of sub-micron aerosol detection platform,and carried out a simulation experiment on the SARS–CoV–2 aerosol in the air by wet-wall cyclone combined with immunomagnetic nanoparticle adsorption sampling and ddPCR.The feasibility of the system in aerosol detection was verified,and the influencing factors in the detection process were experimentally tested.As a result,the sampling efficiency was 29.77%,and extraction efficiency was 98.57%.The minimum detection limit per unit volume of aerosols was 250 copies(102copies/m L,concentration factor 2.5).展开更多
目的本研究旨在评估基于新冠病毒原始毒株与奥密克戎(Omicron)变异株开发的SARS-CoV-2抗体检测试剂,在未接种疫苗的艾滋病病毒感染者(people living with HIV,PLWH)感染Omicron变异株后的检测性能。方法本研究招募了45名未接种新冠疫苗...目的本研究旨在评估基于新冠病毒原始毒株与奥密克戎(Omicron)变异株开发的SARS-CoV-2抗体检测试剂,在未接种疫苗的艾滋病病毒感染者(people living with HIV,PLWH)感染Omicron变异株后的检测性能。方法本研究招募了45名未接种新冠疫苗、首次感染Omicron BA.5毒株的PLWH,并在4个月后进行随访。使用八种针对原始毒株和两种针对Omicron毒株的抗体试剂检测抗体水平,并以针对原始毒株(wild-type,WT)、BA.4/5和XBB.1.5的假病毒中和实验为金标准,使用McNemar与Kappa检验定性结果的一致性,使用斯皮尔曼(Spearman)相关性分析定量结果的相关性。结果原始毒株抗体试剂与WT中和抗体(neutralizing antibody,nAb)的一致性最高(κ值最高为0.483),与Omicron-nAb的一致性明显较低。在定量分析中,原始毒株抗体试剂与WT-nAb呈强相关(r_(s)=0.69~0.85),而与BA.4/5(r_(s)=0.40~0.57)和XBB.1.5(r_(s)=0.43~0.63)-nAb的相关性较弱。二次感染后,原始毒株抗体试剂与Omicron-nAb之间的相关性有所提升。Omicron特异性抗体试剂与Omicron-nAb的95%一致性界限更窄。结论在未接种疫苗的PLWH中,原始毒株抗体试剂对Omicron感染后的免疫应答检测存在局限性,研究结果支持开发和应用变异株特异性抗体试剂,以实现更准确的免疫监测和评估。展开更多
目的评价原型株SARS-CoV-2灭活疫苗免疫BALB/c小鼠后对Delta株病毒的体液及细胞免疫效果,为现有疫苗对变异株的保护效果评价以及研发更加安全有效的疫苗提供参考。方法将SARS-CoV-2灭活疫苗经腹腔免疫雌性BALB/c小鼠2次,间隔14 d,以免疫...目的评价原型株SARS-CoV-2灭活疫苗免疫BALB/c小鼠后对Delta株病毒的体液及细胞免疫效果,为现有疫苗对变异株的保护效果评价以及研发更加安全有效的疫苗提供参考。方法将SARS-CoV-2灭活疫苗经腹腔免疫雌性BALB/c小鼠2次,间隔14 d,以免疫PBS作为对照,每组10只。初次免疫后第7、14、21、28、35和42天采集血清,间接ELISA法检测血清中针对Delta株病毒S和N蛋白的结合抗体效价,微量中和试验检测针对Delta株病毒的中和抗体效价。初次免疫后第42天,取小鼠脾脏,进行Elispot检测,评价细胞免疫水平。结果初次免疫后第7天即可检测到S蛋白结合抗体,加强免疫后抗体效价进一步升高,至第21天抗体几何平均滴度(geometric mean titer,GMT)为89144;而初次免疫后N蛋白结合抗体水平较低,加强免疫后迅速升高,与S蛋白抗体水平相当。初次免疫后第7、14天小鼠中和抗体阳转数为4/10和8/10,加强免疫后全部小鼠抗体阳转,中和抗体GMT达391。初次免疫后第42天,疫苗组IFNγ和IL-2平均斑点数均显著高于对照组(t分别为8.094和13.08,P均<0.0001)。结论SARS-CoV-2灭活疫苗2次免疫能够有效刺激小鼠产生针对Delta株病毒的体液免疫和细胞免疫。展开更多
基金supported by the NSFC(Nos.61701176 and 62071119)Macao FDCT(No.0065/2020/A2)+4 种基金Natural Science Foundation of Hunan Province of China(Nos.2022JJ50052,2018JJ3130 and 2020JJ5145)Hunan Key R&D Projects(No.2021SK2003)Nanjing Important Science&Technology Specific Projects(No.2021-11005)2022 Special Project for the Construction of Innovative Provinces to Fight the COVID-19 Outbreak(No.2022SK2115)Open Funding of State Key Laboratory of Oral Diseases(No.SKLOD2022OF05)。
文摘The SARS–CoV–2 virus is released from an infectious source(such as a sick person)and adsorbed on aerosols,which can form pathogenic microorganism aerosols,which can affect human health through airborne transmission.Efficient sampling and accurate detection of microorganisms in aerosols are the premise and basis for studying their properties and evaluating their hazard.In this study,we built a set of sub-micron aerosol detection platform,and carried out a simulation experiment on the SARS–CoV–2 aerosol in the air by wet-wall cyclone combined with immunomagnetic nanoparticle adsorption sampling and ddPCR.The feasibility of the system in aerosol detection was verified,and the influencing factors in the detection process were experimentally tested.As a result,the sampling efficiency was 29.77%,and extraction efficiency was 98.57%.The minimum detection limit per unit volume of aerosols was 250 copies(102copies/m L,concentration factor 2.5).
文摘目的本研究旨在评估基于新冠病毒原始毒株与奥密克戎(Omicron)变异株开发的SARS-CoV-2抗体检测试剂,在未接种疫苗的艾滋病病毒感染者(people living with HIV,PLWH)感染Omicron变异株后的检测性能。方法本研究招募了45名未接种新冠疫苗、首次感染Omicron BA.5毒株的PLWH,并在4个月后进行随访。使用八种针对原始毒株和两种针对Omicron毒株的抗体试剂检测抗体水平,并以针对原始毒株(wild-type,WT)、BA.4/5和XBB.1.5的假病毒中和实验为金标准,使用McNemar与Kappa检验定性结果的一致性,使用斯皮尔曼(Spearman)相关性分析定量结果的相关性。结果原始毒株抗体试剂与WT中和抗体(neutralizing antibody,nAb)的一致性最高(κ值最高为0.483),与Omicron-nAb的一致性明显较低。在定量分析中,原始毒株抗体试剂与WT-nAb呈强相关(r_(s)=0.69~0.85),而与BA.4/5(r_(s)=0.40~0.57)和XBB.1.5(r_(s)=0.43~0.63)-nAb的相关性较弱。二次感染后,原始毒株抗体试剂与Omicron-nAb之间的相关性有所提升。Omicron特异性抗体试剂与Omicron-nAb的95%一致性界限更窄。结论在未接种疫苗的PLWH中,原始毒株抗体试剂对Omicron感染后的免疫应答检测存在局限性,研究结果支持开发和应用变异株特异性抗体试剂,以实现更准确的免疫监测和评估。
文摘目的评价原型株SARS-CoV-2灭活疫苗免疫BALB/c小鼠后对Delta株病毒的体液及细胞免疫效果,为现有疫苗对变异株的保护效果评价以及研发更加安全有效的疫苗提供参考。方法将SARS-CoV-2灭活疫苗经腹腔免疫雌性BALB/c小鼠2次,间隔14 d,以免疫PBS作为对照,每组10只。初次免疫后第7、14、21、28、35和42天采集血清,间接ELISA法检测血清中针对Delta株病毒S和N蛋白的结合抗体效价,微量中和试验检测针对Delta株病毒的中和抗体效价。初次免疫后第42天,取小鼠脾脏,进行Elispot检测,评价细胞免疫水平。结果初次免疫后第7天即可检测到S蛋白结合抗体,加强免疫后抗体效价进一步升高,至第21天抗体几何平均滴度(geometric mean titer,GMT)为89144;而初次免疫后N蛋白结合抗体水平较低,加强免疫后迅速升高,与S蛋白抗体水平相当。初次免疫后第7、14天小鼠中和抗体阳转数为4/10和8/10,加强免疫后全部小鼠抗体阳转,中和抗体GMT达391。初次免疫后第42天,疫苗组IFNγ和IL-2平均斑点数均显著高于对照组(t分别为8.094和13.08,P均<0.0001)。结论SARS-CoV-2灭活疫苗2次免疫能够有效刺激小鼠产生针对Delta株病毒的体液免疫和细胞免疫。
